CreatorsPublishersAdvertisers
View more in
Cancer

Could MRD Negativity Become A Suitable Surrogate Endpoint in Multiple Myeloma Trials?

oncnursingnews.com
 2021-09-05

Cover picture for the articleThe prognostic value of minimal residual disease negativity in multiple myeloma may make it a suitable surrogate endpoint in clinical trials, according to a group of researchers. Authors of a paper recently published in Clinical Care Research suggest that as health care providers increasingly use minimal residual disease (MRD) assessment...

www.oncnursingnews.com

Comments / 0

Comments / 0